Achondroplasia - Pipeline Review, H2 2018 - ResearchAndMarkets.com
Sep. 13, 2018
DUBLIN--(BUSINESS WIRE)--Sep 13, 2018--The "Achondroplasia - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
This pipeline guide provides comprehensive information on the therapeutics under development for Achondroplasia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Achondroplasia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Achondroplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 2 respectively.
This pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies FeaturedAscendis Pharma A/S BioClin Therapeutics Inc. BioMarin Pharmaceutical Inc. Ribomic Inc.
Key Topics Covered
2. Report Coverage
3. Achondroplasia - Overview
4. Achondroplasia - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Products under Development by Companies
8. Achondroplasia - Therapeutics Assessment
9. Assessment by Target
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Achondroplasia - Companies Involved in Therapeutics Development
14. Ascendis Pharma A/S
15. BioClin Therapeutics Inc.
16. BioMarin Pharmaceutical Inc.
17. Ribomic Inc.
18. Achondroplasia - Drug Profiles
19. ACP-015 - Drug Profile
20. B-701 - Drug Profile
21. infigratinib - Drug Profile
22. RBM-007 - Drug Profile
23. TA-46 - Drug Profile
24. vosoritide - Drug Profile
25. Achondroplasia - Dormant Projects
26. Achondroplasia - Product Development Milestones
Featured News & Press Releases
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9xhx4v/achondroplasia?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180913006036/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/13/2018 03:56 PM/DISC: 09/13/2018 03:56 PM